Meningiomas and schwannomas: Molecular subgroup classification found by expression arrays

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 493-504

  Martinez Glez, Victor ^a   Franco Hernandez, Carmen ^a   Alvarez, Luis ^a   De Campos, Jose M ^b   Isla, Alberto ^a   Vaquero, Jesus ^c   Lassaletta, Luis ^a   Casartelli, Cacilda ^d   Rey, Juan A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gene expression; Meningiomas; Microarray; NF2; Schwannomas

Indexed keywords

MERLIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 22Q; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MENINX; NEURILEMOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; DNA, COMPLEMENTARY; DNA, NEOPLASM; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICROSATELLITE REPEATS; MIDDLE AGED; NEURILEMMOMA; NEUROFIBROMATOSIS 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 64549116846     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000174     Document Type: Article

References (59)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO Classification of Tumours of the central nervous system. Acta Neuropathol (Berl) 114: 97-109, 2007.
2. Rey JA, Bello MJ, de Campos JM, Kusak E and Moreno S: Chromosomal involvement secondary to -22 in human meningiomas. Cancer Genet Cytogenet 33: 275-290, 1988.
3. Louis DN, Scheithauer BW, Budka H, von Deimling A and Kepes JJ: Meningiomas. In: World Health Classification of Tumors: Pathology and Geentics of Tumors of the Nervous System. Kleihues P and Cavenee WK (eds). IARC Press, Lyon, pp176-184, 2000.
4. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, Aminoso C, de Campos JM, Isla A, Vaquero J and Rey JA: Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42: 314-319, 2005.
5. Van Tilborg AA, Morolli B, Giphart-Gassler M, de Vries A, van Geenen DA, Lurkin I, Kros JM and Zwarthoff EC: Lack of genetic and epigenetic changes in meningiomas without NF2 loss. J Pathol 208: 564-573, 2006.
6. Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, Lomas J, de Campos JM, Kusak ME, Vaquero J, Isla A, Gutierrez M, Sarasa JL and Rey JA: DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol (Berl) 108: 413-421, 2004.
7. Liu Y, Pang JC, Dong S, Mao B, Poon WS and Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36: 416-425, 2005.
8. Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestana A and Rey JA: Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9: 296-298, 1994.
9. Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestana A and Rey JA: NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18: 2231-2239, 1999.
10. Perry A, Gutmann DH and Reifenberger G: Molecular pathogenesis of meningiomas. J Neurooncol 70: 183-202, 2004.
11. Neff BA, Wellin DB, Akhmametyeva E and Chang LS: The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otol Neurotol 27: 197-208, 2006.
12. Antinheimo J, Sallinen SL, Sallinen P, Haapasalo H, Helin H, Horelli-Kuitunen N, Wessman M, Sainio M, Jaaskelainen J and Carpen O: Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH). Acta Neurochir (Wien) 142: 1099-1104, 2000.
13. Bruder CE, Ichimura K, Tingb O, Hirakawa K, Komatsuzaki A, Tamura A, Yuasa Y, Collins VP and Dumanski JP: A group of schwannomas with interstitial deletions on 22q located outside the NF2 locus shows no detectable mutations in the NF2 gene. Hum Genet 104: 418-424, 1999.
14. Leone PE, Bello MJ, Mendiola M, Kusak ME, de Campos JM, Vaquero J, Sarasa JL, Pestana A and Rey JA: Allelic status of 1p, 14q, and 22q and NF2 gene mutations in sporadic schwannomas. Int J Mol Med 1: 889-892, 1998.
15. Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM and Evans DG: Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. J Med Genet 40: 802-806, 2003.
16. Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Arjona D, Campos JM, Vaquero J, Isla A, Lassaletta L, Gutierrez M, Sarasa JL and Rey JA: CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas. Clin Cancer Res 9: 5601-5606, 2003.
17. Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, Saito Y, Kochi M, Kuratsu J, Saya H and Ushio Y: Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 6: 441-454, 2001.
18. Bello MJ, Martinez-Glez V, Franco-Hernandez C, Pefla-Granero C, de Campos JM, Isla A, Lassaletta L, Vaquero J and Rey JA: DNA methylation pattern in 16 tumor-related genes in schwannomas. Cancer Genet Cytogenet 172: 84-86, 2007.
19. Lomas J, Bello MJ, Alonso ME, Gonzalez-Gomez P, Arjona D, Kusak ME, de Campos JM, Sarasa JL and Rey JA: Loss of chromosome 22 and absence of NF2 gene mutation in a case of multiple meningiomas. Hum Pathol 33: 375-378, 2002.
20. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002.
21. Michiels S, Koscielny S and Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488-492, 2005.
22. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101: 9309-9314, 2004.
23. Wen PY and Drappatz J: Novel therapies for meningiomas. Expert Rev Neurother 6: 1447-1464, 2006.
24. Fathallah-Shaykh HM, He B, Zhao LJ, Engelhard HH, Cerullo L, Lichtor T, Byrne R, Munoz L, Von Roenn K, Rosseau GL, Glick R, Sherman C and Farooq K: Genomic expression discovery predicts pathways and opposing functions behind phenotypes. J Biol Chem 278: 23830-23833, 2003.
25. Hanemann CO, Bartelt-Kirbach B, Diebold R, Kampchen K, Langmesser S and Utermark T: Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol 32: 605-614, 2006.
26. Martinez-Glez V, Franco-Hernandez C and Rey JA: Microarray gene expression profiling in meningiomas and schwannomas. Curr Med Chem 15: 826-833, 2008.
27. Oh MK, Scoles DR, Haipek C, Strand AD, Gutmann DH, Olson JM and Pulst SM: Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. J Cell Biochem 90: 1068-1078, 2003.
28. Sayagues JM, Tabernero MD, Maillo A, Trelles O, Espinosa AB, Sarasquete ME, Merino M, Rasillo A, Vera JF, Santos-Briz A, de Alava E, Garcia-Macia MC and Orfao A: Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. J Neuropathol Exp Neurol 65: 445-454, 2006.
29. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG and Perry A: Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 161: 665-672, 2002.
30. Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B and Chang LS: cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 23: 736-748, 2002.
31. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G and Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 114: 249-256, 2005.
32. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA and de la Chapelle A: Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56: 3331-3337, 1996.
33. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucma J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363: 515-521, 1993.
34. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G and Lichter P: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94: 14719-14724, 1997.
35. Kluwe L, Nygren AO, Errami A, Heinrich B, Matthies C, Tatagiba M and Mautner V: Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer 42: 384-391, 2005.
36. Martinez-Glez V, Franco-Hernandez C, Lomas J, Pena-Granero C, de Campos JM, Isla A and Rey JA: Multiplex ligation-dependent probe amplification (MLPA) screening in meningioma. Cancer Genet Cytogenet 173: 170-172, 2007.
37. Pelz AF, Klawund P, Skalej M, Wieacker P, Kirches E, Schneider T and Mawrin C: Novel chromosomal aberrations in a recurrent malignant meningioma. Cancer Genet Cytogenet 174: 48-53, 2007.
38. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP and Reifenberger G: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58: 29-33, 1998.
39. Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B, Duerr EM, Lenartz D, Marsh DJ, Schramm J, Wiestler OD, Parsons R, Eng C and von Deimling A: Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol 24: 3-8, 1998.
40. Lassaletta L, Bello MJ, Del Rio L, Alfonso C, Roda JM, Rey JA and Gavilan J: DNA methylation of multiple genes in vestibular schwannoma: relationship with clinical and radiological findings. Otol Neurotol 27: 1180-1185, 2006.
41. Boultwood J and Wainscoat JS: Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 138: 3-11, 2007.
42. Hesson LB, Cooper WN and Latif F: The role of RASSF1 A methylation in cancer. Dis Markers 23: 73-87, 2007.
43. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J and Denissenko MF: Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26: 943-950, 2005.
44. Kletsas D, Pratsinis H, Mariatos G, Zacharatos P and Gorgoulis VG: The proinflammatory phenotype of senescent cells: the p53-mediated ICAM-1 expression. Ann NY Acad Sci 1019: 330-332, 2004.
45. Kondraganti S, Gondi CS, McCutcheon I, Dinh DH, Gujrati M, Rao JS and Olivero WC: RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol 28: 1353-1360, 2006.
46. Salajegheh M, Rudnicki A and Smith TW: Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. Appl Immunohistochem Mol Morphol 13: 184-189, 2005.
47. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC and Lawrence DA: Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964-33968, 2001.
48. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S and Kwaan HC: Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96: 2593-2600, 1995.
49. Barbieri F, Bajetto A, Porcile C, Pattarozzi A, Massa A, Lunardi G, Zona G, Dorcaratto A, Ravetti JL, Spaziante R, Schettini G and Florio T: CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation. Ann NY Acad Sci 1090: 332-343, 2006.
50. Hiratsuka S, Minowa O, Kuno J, Noda T and Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354, 1998.
51. Al Khalaf HH, Lach B, Allam A, AlKhani A, Alrokayan SA and Aboussekhra A: The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells. J Neurooncol 83: 9-15, 2007.
52. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, Zhivotovsky B, Leibiger I, Grander D and Pokrovskaja K: Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 279: 24152-24162, 2004.
53. Wu S, Murrell GA and Wang Y: Interferon-alpha (Intron A) up-regulates urokinase-type plasminogen activator receptor gene expression. Cancer Immunol Immunother 51: 248-254, 2002.
54. Siddique K, Yanamandra N, Gujrati M, Dinh D, Rao JS and Olivero W: Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. Int J Oncol 22: 289-294, 2003.
55. Hrabec E, Naduk J, Strek M and Hrabec Z: Type IV collagenases (MMP-2 and MMP-9) and their substrates - intracellular proteins, hormones, cytokines, chemokines and their receptors. Postepy Biochem 53: 37-45, 2007.
56. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, VandenBerg SR and Lal A: Molecular signatures define two main classes of meningiomas. Mol Cancer 6: 64, 2007.
57. Smith JS, Lal A, Harmon-Smith M, Bollen AW and McDermott MW: Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg 106: 1034-1040, 2007.
58. Scoles DR, Qin Y, Nguyen V, Gutmann DH and Pulst SM: HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. Biochem Biophys Res Commun 335: 385-392, 2005.
59. Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149, 2005.